Spruce Biosciences secures up to $50M in growth capital
Seeking Alpha News (Thu, 8-Jan 8:58 AM ET)
Spruce Biosciences Secures $50 Million Term Loan Facility
TipRanks (Thu, 8-Jan 8:51 AM ET)
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Business Wire (Thu, 8-Jan 8:00 AM ET)
Business Wire (Mon, 15-Dec 8:00 AM ET)
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Business Wire (Mon, 10-Nov 4:05 PM ET)
Market Chameleon (Wed, 8-Oct 5:43 AM ET)
FDA Breakthrough Therapy Designation Puts Spotlight on Spruce Biosciences' TA-ERT for Rare Disease
Market Chameleon (Mon, 6-Oct 6:31 AM ET)
Market Chameleon (Mon, 6-Oct 4:21 AM ET)
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Spruce Biosciences trades on the NASDAQ stock market under the symbol SPRB.
As of January 13, 2026, SPRB stock price climbed to $81.50 with 16,164 million shares trading.
SPRB has a beta of -23.45, meaning it tends to be less sensitive to market movements. SPRB has a correlation of 0.24 to the broad based SPY ETF.
SPRB has a market cap of $87.24 million. This is considered a Micro Cap stock.
Last quarter Spruce Biosciences reported $0 in Revenue and -$14.58 earnings per share. This fell short of revenue expectation by $-200,000 and exceeded earnings estimates by $.98.
SPRB support price is $73.38 and resistance is $82.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRB shares will trade within this expected range on the day.
